Exenatide Affects Circulating Cardiovascular Risk Biomarkers Independently of Changes in Body Composition

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

(2009) Le Thi Kim Chung et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus

(2009) R. A. DeFronzo   DIABETES

One-Year Treatment With Exenatide Improves  -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial

(2009) M. C. Bunck et al.   DIABETES CARE

Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue

(2009) J. Jendle et al.   DIABETES OBESITY & METABOLISM

Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels

(2008) L. Li et al.   DIABETES OBESITY & METABOLISM

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

(2008) J.-P. Courrèges et al.   DIABETIC MEDICINE

Role of Body Fat Distribution and the Metabolic Complications of Obesity

(2008) Michael D. Jensen   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Role of Incretins in Glucose Homeostasis and Diabetes Treatment

(2008) W. Kim et al.   PHARMACOLOGICAL REVIEWS